Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio as predictors of 12-week treatment response and drug persistence of anti-tumor necrosis factor-α agents in patients with rheumatoid arthritis: a retrospective chart review analysis

• Published in: Rheumatology international 2019-05, Vol.39 (5), p.859-868
• Main Authors: Lee, Han-Na, Kim, Yun-Kyung, Kim, Geun-Tae, Ahn, Eunyoung, So, Min Wook, Sohn, Dong Hyun, Lee, Seung-Geun
• Format: Article
• Language: English
• Subjects: Adult; Arthritis, Rheumatoid - blood; Arthritis, Rheumatoid - drug therapy; Case-Control Studies; Female; Humans; Leukocyte Count; Lymphocyte Count; Lymphocytes; Medication Adherence; Medicine; Medicine & Public Health; Middle Aged; Necrosis; Neutrophils; Observational Research; Platelet Count; Prognosis; Retrospective Studies; Rheumatoid arthritis; Rheumatology; Treatment Outcome; Tumor Necrosis Factor Inhibitors - therapeutic use; Tumor necrosis factor-TNF
• ISSN: 0172-8172; 1437-160X
• DOI: 10.1007/s00296-019-04276-x

Data are scarce regarding the association of neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) with treatment response and persistence of anti-TNF-α agents in patients with rheumatoid arthritis (RA). Thus, we investigated whether baseline NLR and PLR could predict 12-week treatment response and long-term persistence of anti-TNF-α agents in RA patients. This is a retrospective chart review analysis of 82 women with RA who started anti-TNF-α agents as the first-line biologic therapy and 328 healthy age-matched women. RA patients were divided into high and low baseline NLR or PLR subgroups using the median split. European League against Rheumatism (EULAR) treatment response was evaluated at 12 weeks. RA patients had significantly higher NLR and PLR than controls. High baseline NLR and PLR groups showed higher 12-week EULAR non-response rate than low NLR (30% vs 7.1%, p  = 0.01) and PLR groups (27.5% vs 9.5%, p  = 0.047), respectively. After adjusting for confounding factors, high baseline NLR (OR 5.57, p  = 0.014) and PLR (OR 4.24, p  = 0.04) were significantly associated with a higher risk of EULAR non-response at 12 weeks. During the study period, 47 (57.3%) RA patients (lack of efficacy: n  = 31; adverse events: n  = 16) discontinued anti-TNF-α agents. High baseline NLR was associated with an increased risk of anti-TNF-α agent withdrawal due to lack of efficacy (HR 2.12, p  = 0.045). Our data suggest that baseline NLR and PLR are useful markers for predicting the treatment outcome of anti-TNF-α agents in RA patients.